Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25044269 | 0.79 | DRD2 (0.41) | DRD2DRD4DRD3 | |
| SCHEMBL21863437 | 0.79 | DRD2 (0.41) | DRD2DRD4DRD3CYP17A1CYP1A2 | |
| SCHEMBL24103795 | 0.76 | TSHR (0.36) | CYP17A1CYP1A2TLR8KDM4EHTT | |
| SCHEMBL12145712 | 0.74 | DRD4 (0.41) | DRD4DRD3CYP17A1CYP1A2HTT | |
| SCHEMBL23938203 | 0.73 | CYP17A1 (0.33) | DRD2DRD4DRD3CYP17A1CYP1A2 | |
| SCHEMBL21893906 | 0.73 | PDE4B (0.33) | CYP17A1CYP1A2TLR8NPC1RAB9A | |
| SCHEMBL5848633 | 0.72 | DRD2 (0.38) | DRD2DRD4DRD3NPC1RAB9A | |
| SCHEMBL23938202 | 0.72 | CYP1A2 (0.35) | CYP17A1CYP1A2TLR8 | |
| SCHEMBL24729869 | 0.68 | DRD2 (0.40) | DRD2DRD4DRD3CYP17A1CYP1A2 | |
| SCHEMBL21631042 | 0.67 | IDO1 (0.41) | DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230050653-A1 | ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230050653-A1 | ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | ROCK1, CYP11B1, CYP4A11 | DRD2 3504/4885DRD4 3371/4885DRD3 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.